Volume 21, Issue 1 - Medical Writing in Oncology

Journal Watch

Authors: Nancy Milligan, Stephen Gilliver

Abstract

References

1. Getz KA, Zuckerman R, Cropp AB, Hindle AL, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf J 2011;45(03):265–75.
2. Del Parigi A. Industry funded clinical trials: bias and quality. Curr Med Res Opin 2012;28(1):1–3.
3. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290(7):921–8.
4. Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB. Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008;32(10):1531–6.
5. Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 2008;66(6):767–73.
6. Shaw D. The ICMJE's definition of authorship is illogical and unethical. BMJ 2011;343:bmj.d7192.
7. Lippert S, Callaham ML, Lo B. Perceptions of conflict of interest disclosures among peer reviewers. PLoS One 2011;6(11):e26900.
8. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. [cited 30 November 2011]. Available from: http://www.icmje.org/urm_full.pdf
9. Callaham ML. Journal policy on ethics in scientific publication. Ann Emerg Med 2003;41(1):82–9.
10. Annals of Emergency Medicine. Annals conflict of interest policy for editors and reviewers. [cited 1 December 2011]. Available from: http://www.annemergmed.com/content/instauth#conflict
11. Isaacs D. Conflict of interest: no such thing as a free lunch. J Paediatr Child Health 2011;47(10):679–80.